Streetbeat News

Analyst Ratings

W

Needham analyst Anna Andreeva reiterated a Buy rating on Wayfair (NYSE:W) and maintained a $75 price target.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 5:07 pm

MOS

Mosaic (MOS) shares surged following the announcement of Q4 revenue results that exceeded expectations. Additionally, Scotiabank upgraded MOS from Sector Perform to Sector Outperform, setting a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 5:06 pm

NABL

Needham analyst Mike Cikos has reiterated a Buy rating on N-able (NYSE:NABL) and maintained a price target of $16.5.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 5:05 pm

PANW

Palo Alto Networks (NASDAQ:PANW) has seen a notable options trading activity, with a bearish sentiment prevailing among traders. Analysis revealed 63 unusual trades, with 42% bullish and 57% bearish. The trading focused on a price band between $200.0 and $367.5. Noteworthy options activity included both puts and calls with varying sentiments and expiration dates. The company's current market status shows a 5.16% increase in stock price to $275.49, with a neutral RSI indicator. Analysts have issued ratings with a consensus target price of $376.0, varying from $345 to $425.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:01 pm

CDNS

Cadence Design Systems (NASDAQ:CDNS) has seen significant options activity, indicating mixed sentiment among high-rolling investors, with 50% bullish and 50% bearish. The activity, highlighted by Benzinga, includes 14 options trades with a focus on a price band between $250.0 and $410.0. The largest trades include both bullish and bearish calls with varying strike prices and expiration dates. CDNS's stock is currently up 4.93% at $305.09, with analysts providing mixed ratings and price targets ranging from $280 to $350. The company, a provider of electronic design automation software, benefits from the digitalization of end markets and the convergence of semiconductor and systems companies.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:01 pm

IFF

Analyst ratings for Intl Flavors & Fragrances (IFF) show diverse opinions with a recent shift towards more positive evaluations. Over the last three months, 11 analysts have provided ratings, with a notable increase in the average 12-month price target to $85.73, up 8.52% from $79.00. Recent actions include both upgrades and downgrades, reflecting dynamic market conditions and company performance. Despite the positive analyst sentiment, IFF faces financial challenges, including a -4.15% decline in revenue growth and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:00 pm

NPCE

NeuroPace (NASDAQ:NPCE) has been evaluated by 4 analysts over the last three months, showing a diverse range of opinions. The average 12-month price target for NPCE is now $14.75, up from $9.67, indicating a positive outlook. The company, focusing on medical devices for epilepsy, reported a 47.23% revenue growth and a net margin of -44.18%. Despite a high debt-to-equity ratio of 4.38, its market capitalization and revenue growth surpass industry averages.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:00 pm

CE

Analyst ratings for Celanese (NYSE:CE) show varied perspectives, with recent adjustments reflecting a generally positive outlook. The average 12-month price target has increased to $162.5, up 11.63% from $145.57, indicating bullish sentiment. Despite a negative revenue trend of -5.66% as of December 31, 2023, Celanese's financial health remains strong with a high net margin of 27.17% and ROE of 10.28%. The company's debt-to-equity ratio of 1.98 suggests higher financial risk.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:00 pm

TYL

DA Davidson analyst Peter Heckmann has maintained a Neutral rating on Tyler Technologies (TYL) and increased the price target from $412 to $434.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 5:00 pm

NEO

Goldman Sachs has reaffirmed its Buy rating on NeoGenomics (NASDAQ:NEO), raising the price target from $17.00 to $19.00. Following this update, NeoGenomics' shares saw a 1.27% increase, trading at $16.69. The new price target suggests a potential 13.84% upside. NeoGenomics specializes in cancer-focused genetic testing services in the U.S. and Switzerland, with the majority of its revenue coming from Clinical Services.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:00 pm